HemaSphere (Aug 2023)
P561: REVUMENIB IN PATIENTS WITH ACUTE LEUKEMIAS: COMPASSIONATE USE PROGRAM EXPERIENCE
- Jeffrey Rubnitz,
- Ghayas C. Issa,
- Eytan M. Stein,
- Neerav Shukla,
- Wendy Stock,
- Andrius Žučenka,
- Sajad Khazal,
- Nandita Khera,
- Elliot Stieglitz,
- Jeremy Rubinstein,
- Galit Rosen,
- Rachel Ghiraldi,
- Huy Van Nguyen,
- Nicole Mcneer,
- C. Michel Zwaan
Affiliations
- Jeffrey Rubnitz
- 1 St. Jude Children’s Research Hospital, Memphis, TN, United States
- Ghayas C. Issa
- 2 The University of Texas MD Anderson Cancer Center, Houston, TX, United States
- Eytan M. Stein
- 3 Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Neerav Shukla
- 3 Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Wendy Stock
- 4 University of Chicago, Chicago, IL, United States
- Andrius Žučenka
- 5 Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
- Sajad Khazal
- 2 The University of Texas MD Anderson Cancer Center, Houston, TX, United States
- Nandita Khera
- 7 The Mayo Clinic, Phoenix, AZ, United States
- Elliot Stieglitz
- 8 The University of California, San Francisco, San Francisco, CA, United States
- Jeremy Rubinstein
- 9 Cincinatti Children’s Hospital, Cincinnati, OH, United States
- Galit Rosen
- 10 Syndax Pharmaceuticals, Inc., Waltham, MA, United States
- Rachel Ghiraldi
- 10 Syndax Pharmaceuticals, Inc., Waltham, MA, United States
- Huy Van Nguyen
- 10 Syndax Pharmaceuticals, Inc., Waltham, MA, United States
- Nicole Mcneer
- 10 Syndax Pharmaceuticals, Inc., Waltham, MA, United States
- C. Michel Zwaan
- 11 Princess Máxima Center, Utrecht, and Erasmus MC, Rotterdam, The Netherlands
- DOI
- https://doi.org/10.1097/01.HS9.0000969148.22118.7f
- Journal volume & issue
-
Vol. 7
p. e221187f
Abstract
No abstracts available.